ReviewProstate cancer and prostatic diseases2025
Biopsy strategies in the era of mpMRI: a comprehensive review.
Review in Prostate cancer and prostatic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Feasibility study on the implementation of a mobile high-resolution PET/CT scanner for surgical specimens: exploring clinical applications and practical considerations.European journal of nuclear medicine and molecular imaging · 2025Trial
- The importance of targeted plus perilesional prostate biopsy in prostate cancer management (diagnosis and treatment)-real world evidence of a tertiary centre.International urology and nephrology · 2026Article
- Optimising the prostate cancer diagnostic pathway in a tertiary hospital in Karachi: a two-cycle quality improvement project.BMJ open quality · 2026Article
- Focal Therapy for Prostate Cancer: State of the Art, Physical Principles, Potentials, and Challenges.Cancers · 2026Review
- Automated Prostate Cancer Detection on T2-Weighted MRI Using a Dual-Stream Attention Network: A Study on Private Saudi Clinical Data and Public Benchmark Datasets.Journal of clinical medicine · 2026Article
- Diagnostic and Clinical Impact of Imaging Modality on PSA Density: TRUS Versus MRI in Gray-Zone Prostate Cancer.Current oncology (Toronto, Ont.) · 2026Article
- Screening policy changes and prostate cancer epidemiology: 20-year trends in diagnosis, treatment, incidence, and mortality.World journal of urology · 2026Article
- Diagnostic Performance of Perineal MRI-US Fusion Prostate Biopsy: A Single-Center Prospective Cohort Analysis.Biomedicines · 2026Article
- Incremental diagnostic value of MRI PI-RADS classification combined with PSA density for prostate cancer.Frontiers in oncology · 2026Article
- Multimodality focal therapy for prostate cancer: outcome of theProstate international · 2025Article
- Novel ultrasound scoring system to guide cognitive fusion-targeted biopsy: a prospective study.Abdominal radiology (New York) · 2025Article
- Patients with multiple mpMRI region of interests: should we omit targeted biopsies of secondary lesions?Abdominal radiology (New York) · 2025Article
- The evolving role of positron emission tomography in precision prostate cancer biopsy.European journal of clinical investigation · 2025Review
- Evaluating [Current oncology (Toronto, Ont.) · 2024Article
- High-Intensity Focus Ultrasound Ablation in Prostate Cancer: A Systematic Review.Journal of personalized medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince its initial description the prostate biopsy technique for detection of prostate cancer (PCA) has constantly evolved. Multiparametric magnetic resonance imaging (mpMRI) has been proven to have a sensitivity exceeding 90% to detect the index lesion. This narrative review discusses the evidence around several biopsy strategies, especially in the context of patients that might be eligible for focal therapy.
methodA non-systematic literature research was performed on February 15th 2024 using the Medical Literature Analysis and Retrieval System Online (Medline), Web of Science and Google Scholar.
resultsThe transrectal (TR) route is associated with an increased postoperative sepsis rate, even with adequate antibiotic prophylaxis. The transperineal (TP) route is now recommended by international guidelines, firstly for its decreased rate of urosepsis. Recent evidence shows a non-inferiority of TP compared to TR route, and even a higher detection rate of clinically significant PCA (csPCA) in the anterior and apical region, that are usually difficult to target using the TR route. Several targeting techniques (cognitive, software-fusion or in-bore) enhance our ability to provide an accurate risk assessment of prostate cancer aggressiveness and burden, while reducing the number of cores and reducing the number of clinically insignificant prostate cancer (ciPCA). While MRI-TB have proven their role, the role of systematic biopsies (SB) is still important because it detects 5-16% of csPCA that would have been missed by MRI-TB alone. The strategies of SB depend mainly on the route used (TR vs. TP) and the number of cores to be collected (10-12 cores vs. saturation biopsies vs. trans-perineal template mapping-biopsies or Ginsburg Protocol vs. regional biopsies).
conclusionSeveral biopsy strategies have been described and should be known when assessing patients for focal therapy. Because MRI systematically under evaluates the lesion size, systematic biopsies, and especially perilesional biopsies, can help to increase sensitivity at the cost of an increased number of cores.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.